Effectiveness and Safety of Mesenchymal Stem Cell Therapy in Long COVID Patients

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

July 1, 2025

Study Completion Date

August 31, 2026

Conditions

Long COVIDPost-Acute COVID-19 Syndrome

Interventions

DRUG

umbilical cord mesenchymal stem cell

intravenous infusion of umbilical cord mesenchymal stem cell

Trial Locations (1)

RECRUITING

Shanghai Changhai Hospital, Shanghai

All Listed Sponsors

lead

Changhai Hospital

OTHER